title: Risk for esophageal neoplasia in Barrett's esophagus patients with mucosal changes indefinite for dysplasia.
abstract: OBJECTIVE
  Patients with Barrett's esophagus (BE) are at increased risk for esophageal adenocarcinoma (EAC) and therefore require surveillance. Biopsies are classified as indefinite for dysplasia (IND) when the significance of epithelial abnormalities is uncertain due to inflammation or sampling. Our aim was to characterize the neoplastic risk of IND in BE patients and to identify predictors of neoplastic risk.
  
  
  METHODS
  Our pathology database from 1992 to 2007 was searched for BE and IND. Progression rates were calculated and univariate analysis was performed to identify predictors for neoplasia progression in BE-IND patients.
  
  
  RESULTS
  Among 85 patients who had a follow-up (FU) biopsy within 1 year, 11 (12.9%) patients had prevalent neoplasia (seven low-grade dysplasia [LGD], two high-grade dysplasia [HGD], and two EAC). Among 82 patients who did not have prevalent neoplasia but had ≥ 1 year FU, 17 progressed to dysplasia (14 LGD, 3 HGD) and 2 developed EAC during a mean FU period of 59 months. The incidence of neoplasia (LGD, HGD, or EAC) and advanced neoplasia (HGD + EAC) was 4.5 and 1.2 cases per 100 patient-years, respectively. Longer length of BE and multi-focal IND on index biopsy were associated with progression to neoplasia.
  
  
  CONCLUSIONS
  Patients with BE-IND carry a significant risk of harboring prevalent dysplasia, but the risk of incident dysplasia is similar to the general BE population. The length of BE and the multifocal IND might tentatively help to identify a patient subpopulation at higher risk of neoplastic progression before more definitive data becomes available.
authors.affiliation: Department of Anatomic Pathology, Cleveland Clinic, Cleveland, Ohio, USA.
authors.forename: Bela
authors.initials: B
authors.lastname: Horvath
authors.forename: Prabhdeep
authors.initials: P
authors.lastname: Singh
authors.forename: Hao
authors.initials: H
authors.lastname: Xie
authors.forename: Prashanthi N
authors.initials: PN
authors.lastname: Thota
authors.forename: Daniela S
authors.initials: DS
authors.lastname: Allende
authors.forename: Rish K
authors.initials: RK
authors.lastname: Pai
authors.forename: Deepa T
authors.initials: DT
authors.lastname: Patil
authors.forename: Thomas P
authors.initials: TP
authors.lastname: Plesec
authors.forename: John R
authors.initials: JR
authors.lastname: Goldblum
authors.forename: Xiuli
authors.initials: X
authors.lastname: Liu
mesh_terms: D000230:Adenocarcinoma / Q000453:epidemiology / Q000209:etiology* / Q000473:pathology*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001471:Barrett Esophagus / Q000150:complications* / Q000453:epidemiology / Q000473:pathology*; D018450:Disease Progression; D004848:Epithelium / Q000473:pathology; D004938:Esophageal Neoplasms / Q000453:epidemiology / Q000209:etiology* / Q000473:pathology*; D004947:Esophagus / Q000473:pathology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D015995:Prevalence; D012306:Risk; D013997:Time Factors
keywords: Barrett's esophagus; dysplasia; esophageal adenocarcinoma